TP53 and hepatocellular carcinoma: Furthermore, Hep3B cells, the p53-null HCC cell line, exhibited a lower response to the cabozantinib and CBD combination treatment than that of HepG2 cells (IC50, 32.1 μM; Figure S2 and Figure 2A).